Yawning and locomotor behavior induced by dopamine receptor agonists in mice and rats

Behavioural Pharmacology

Volumn 21, Issue 3, 2010, Pages 171-181

  Li, Su Min ^a   Collins, Gregory T ^b   Paul, Noel M ^a   Grundt, Peter ^a   Newman, Amy H ^a   Xu, Ming ^c   Grandy, David K ^d   Woods, James H ^b   Katz, Jonathan L ^a  

^a NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

^d OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

7 OH DPAT; BP 897; Dopamine agonist; Dopamine D2 D3 receptor; Knockout mouse; L 741626; PD 128907; PG01037; Quinpirole; U 91356A

Indexed keywords

2 DIPROPYLAMINO 7 HYDROXYTETRALIN; 3,4,4A,10B TETRAHYDRO 4 PROPYL 2H,5H [1]BENZOPYRANO[4,3 B][1,4]OXAZIN 9 OL; 5,6 DIHYDRO 5 (PROPYLAMINO) 4H IMIDAZO[4.5.1 IJ]QUINOLIN 2 (1H) ONE; APOMORPHINE; BP 897; CHOLINERGIC RECEPTOR STIMULATING AGENT; DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; DOPAMINE 3 RECEPTOR BLOCKING AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; HYDROBROMIC ACID; L 741626; N [4 [4 (2,3 DICHLOROPHENYL)PIPERAZIN 1 YL] TRANS BUT 2 ENYL] 4 PYRIDINE 2 YLBENZAMIDE; PG 01035; PHYSOSTIGMINE; PRAMIPEXOLE; QUINELORANE; QUINPIROLE; U 91356A; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; IN VIVO STUDY; KNOCKOUT MOUSE; LOCOMOTION; MOUSE; NONHUMAN; RAT; WILD TYPE; YAWNING;

ANALYSIS OF VARIANCE; ANIMALS; CHOLINESTERASE INHIBITORS; DOPAMINE AGONISTS; DOPAMINE ANTAGONISTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; MICE; MICE, INBRED C3H; MICE, KNOCKOUT; MOTOR ACTIVITY; PHYSOSTIGMINE; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, DOPAMINE D2; YAWNING;

EID: 77952328990     PISSN: 09558810     EISSN: None     Source Type: Journal    
DOI: 10.1097/FBP.0b013e32833a5c68     Document Type: Article

References (29)

1. Boulay D, Depoortere R, Rostene W, Perrault G, Sanger DJ (1999a). Dopamine D3 receptor agonists produce similar decreases in body temperature and locomotor activity in D3 knock-out and wild-type mice. Neuropharmacology 38:555-565.
2. Boulay D, Depoortere R, Perrault G, Borrelli E, Sanger DJ (1999b). Dopamine D2 receptor knock-out mice are insensitive to the hypolocomotor and hypothermic effects of dopamine D2/D3 receptor agonists. Neuropharma-cology 38:1389-1396.
3. Bristow LJ, Cook GP, Gay JC, Kulagowski JJ, Landon L, Murray F, et al. (1996). The behavioural and neurochemical profile of the putative dopamine D3 receptor agonist, (+)-PD 128907, in the rat. Neuropharmacology 35:285-294.
4. Collins GT, Witkin JM, Newman AH, Svensson KA, Grundt P, Cao J, Woods JH (2005). Dopamine agonist-induced yawning in rats: a dopamine D3 receptor-mediated behavior. J Pharmacol Exp Ther 314:310-319.
5. Collins GT, Newman AH, Grundt P, Rice KC, Husbands SM, Chauvignac C, et al. (2007). Yawning and hypothermia in rats: effects of dopamine D3 and D2 agonists and antagonists. Psychopharmacology (Berl) 193:159-1157
6. Daly SA, Waddington JL (1993). Behavioural effects of the putative D-3 dopamine receptor agonist 7-OH-DPAT in relation to other D-2-like agonists. Neuropharmacology 32:509-510.
7. Depoortere R, Perrault G, Sanger DJ (1996). Behavioural effects in the rat of the putative dopamine D3 receptor agonist 7-OH-DPAT: comparison with quinpirole and apomorphine. Psychopharmacology (Berl) 124:231-240.
8. Geter-Douglass B, Katz JL, Alling K, Acri JB, Witkin JM (1997). Characterization of unconditioned behavioral effects of dopamine D3/D2 receptor agonists. J Pharmacol Exp Ther 283:7-15.
9. Gilbert DB, Cooper SJ (1995). 7-OH-DPAT injected into the accumbens reduces locomotion and sucrose ingestion: D3 autoreceptor-mediated effects? Pharmacol Biochem Behav 52:275-280.
10. Grundt PG, Carlson EE, Cao J, Bennett CJ, McElveen E, Taylor M, et al. (2005). Novel Heterocyclic Trans Olefin Analogues of N-4-[4-(2,3-Dichlorophenyl) pi-perazin-1-yl]butylarylcarboxamides as selective probes with high affinity for the dopamine D3 receptor. J Med Chem 48:839-848.
11. Grundt PG, Husband SLJ, Luedtke RR, Taylor M, Newman AH (2007). Analogues of the dopamine D2 receptor antagonist L741,626: binding, function, and SAR. Bioorg Med Chem Lett 17:745-749.
12. Holmgren B, Urbá-Holmgren R (1980). Interaction of cholinergic and dopaminergic influences on yawning behavior. Acta Neurobiol Exp (Wars) 40:633-642.
13. Joyce JN, Millan MJ (2005). Dopamine D3 receptor antagonists as therapeutic agents. Drug Discov Today 10:917-925.
14. Kelly MA, Rubinstein M, Asa SL, Zhang G, Saez C, Bunzow JR, et al. (1997). Pituitary lactotroph hyperplasia and chronic hyperprolactinemia in dopamine D2 receptor-deficient mice. Neuron 19:103-113.
15. Kostrzewa RM, Brus R (1991). Is dopamine-agonist induced yawning behavior a D3 mediated event? Life Sci 48:PL129.
16. Levant B (1997). The D3 dopamine receptor: neurobiology and potential clinical relevance. Pharmacol Rev 49:231-252.
17. Maj J, Rogóz Z, Skuza G (1999). The anticataleptic effect of 7-OH-DPAT: are dopamine D3 receptors involved? J Neural Transm 106:1063-1073.
18. Millan MJ, Seguin L, Gobert A, Cussac D, Brocco M (2004). The role of dopamine D3 compared with D2 receptors in the control of locomotor activity: a combined behavioural and neurochemical analysis with novel, selective antagonists in rats. Psychopharmacology (Berl) 174:341-357.
19. Mogilnicka E, Klimek V (1977). Drugs affecting dopamine neurons and yawning behavior. Pharmacol Biochem Behav 7:303-305.
20. Piercey MF, Moon MW, Sethy VH, Schreur PJKD, Smith MW, Tang AH, VonVoigtlander PF (1996). Pharmacology of U-91356A, an agonist for the dopamine D2 receptor subtype. European Journal of Pharmacology 317:29-38.
21. Newman AH, Grundt P, Nader MA (2005). Dopamine D3 receptor partial agonists and antagonists as potential drug abuse therapeutic agents. J Med Chem 48:3663-3679.
22. Pritchard LM, Logue AD, Hayes S, Welge JA, Xu M, Zhang J, et al. (2003). 7-OH-DPAT and PD 128907 selectively activate the D3 dopamine receptor in a novel environment. Neuropsychopharmacology 28:100-107.
23. Pugsley TA, Davis MD, Akunne HC, MacKenzie RG, Shih YH, Damsma G, et al. (1995). Neurochemical and functional characterization of the preferentially selective dopamine D3 agonist PD 128907. J Pharmacol Exp Ther 275:1355-1366.
24. Rogóz Z, Skuza G (2001). Repeated imipramine treatment enhances the 7-OH-DPAT-induced hyperactivity in rats: the role of dopamine D2 and D3 receptors. Pol J Pharmacol 53:571-576.
25. Sevak RJ, Koek W, Galli A, France CP (2007). Insulin replacement restores the behavioral effects of quinpirole and raclopride in streptozotocin-treated rats. J Pharmacol Exp Ther 320:1216-1223.
26. Shafer RA, Levant B (1998). The D3 dopamine receptor in cellular and organismal function. Psychopharmacology (Berl) 135:1-16.
27. Sokoloff P, Giros B, Martres MP, Bouthenet ML, Schwartz JC (1990). Molecular cloning and characterization of a novel dopamine receptor (D3) as a target for neuroleptics. Nature 347:146-151.
28. Tirelli E, Reggers J, Terry P (1997). Dopamine D2-like receptor agonists in combination with cocaine: absence of interactive effects on locomotor activity. Behav Pharmacol 8:147-159.
29. Xu M, Koeltzow TE, Tirado G, Moratalla R, Cooper DC, Hu X-T, et al. (1997). Dopamine D3 receptor mutant mice exhibit increased behavioral sensitivity to concurrent stimulation of D1 and D2 receptors. Neuron 19:837-848.